Stock TNYA TENAYA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Market Closed - Nasdaq
Other stock markets
 04:00:07 2024-07-12 pm EDT 		5-day change 1st Jan Change
3.495 USD -0.14% Intraday chart for Tenaya Therapeutics, Inc. +19.69% +7.87%
Jul. 01 Tenaya Therapeutics, Inc.(NasdaqGS:TNYA) added to Russell Microcap Growth Index CI
Jul. 01 Tenaya Therapeutics, Inc.(NasdaqGS:TNYA) added to Russell 2500 Growth Index CI

Evolution of the average Target Price on Tenaya Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ff9dd843a50584.zQ_mUCN5trSbWRetQxBRgGrCaSo8mC-18kd1l-iansA.o32INQ4QzubMM3zbEnpj8FOoClx4_U6DyyQ88Nj0xK-jXolkaj758tQAWg~758e38e931e09384f97f5e3169a36a4f

Analyst Recommendations on Tenaya Therapeutics, Inc.

William Blair Starts Tenaya Therapeutics With Outperform Rating MT
Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $17 From $18, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $14 From $13, Keeps Overweight Rating MT
Chardan Trims Price Target on Tenaya Therapeutics to $23 From $24, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Tenaya Therapeutics to $18 From $25, Maintains Buy Rating MT
Chardan Cuts Price Target on Tenaya Therapeutics to $24 From $28, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $13 From $15, Maintains Overweight Rating MT
Chardan Trims Price Target on Tenaya Therapeutics to $28 From $30, Affirms Buy Rating MT
Canaccord Genuity Starts Tenaya Therapeutics at Buy With $21 Price Target MT
Chardan Research Trims Tenaya Therapeutics' Price Target to $30 From $31, Maintains Buy Rating MT
HC Wainwright Starts Tenaya Therapeutics at Buy With $25 Price Target MT
Morgan Stanley Lowers Tenaya Therapeutics' Price Target to $15 From $19, Maintains Overweight Rating MT
Morgan Stanley Adjusts Tenaya Therapeutics' Price Target to $19 from $31, Keeps Overweight Rating MT
TENAYA THERAPEUTICS : Chardan Starts Tenaya Therapeutics at Buy with $37 Price Target on Heart Disease Drugs' Potential MT
TENAYA THERAPEUTICS : Cowen Starts Tenaya Therapeutics at Outperform MT
TENAYA THERAPEUTICS : Morgan Stanley Initiates Coverage on Tenaya Therapeutics With Overweight Rating, $31 Price Target MT
TENAYA THERAPEUTICS : Piper Sandler Starts Tenaya Therapeutics at Overweight With $40 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.51 USD
Average target price
18.62 USD
Spread / Average Target
+430.63%
High Price Target
40 USD
Spread / Highest target
+1,039.60%
Low Price Target
7 USD
Spread / Lowest Target
+99.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tenaya Therapeutics, Inc.

William Blair & Co.
Canaccord Genuity
Morgan Stanley
Chardan Research
HC Wainwright
Piper Sandler
Chardan
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TNYA Stock
  4. Consensus Tenaya Therapeutics, Inc.